Welcome to our dedicated page for XPHYF news (Ticker: XPHYF), a resource for investors and traders seeking the latest updates and insights on XPHYF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect XPHYF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of XPHYF's position in the market.
XPhyto Therapeutics Corp. has successfully completed the final tranche of its private placement, raising $788,400 through the issuance of 2,190,000 units priced at $0.36 each. Each unit includes one common share and one-half share purchase warrant, exercisable at $0.50 for two years. Proceeds from this financing, totaling $3.6 million, will support research, development, and working capital. Notably, all issued securities are subject to a four-month regulatory hold period. XPhyto is focused on advancing drug delivery and diagnostic products in European markets.
XPhyto Therapeutics Corp. (CSE:XPHY)(OTC:XPHYF)(FSE:4XT) announced the closing of its second tranche of a private placement, raising $1.8 million by issuing 5 million units at $0.36 each. Each unit includes one common share and half a warrant, exercisable at $0.50 for two years. The company utilized $144,000 in finder's fees and plans to allocate proceeds for research, development, and working capital. Additionally, it will issue 442,839 shares to settle €156,000 of debt, preserving cash for operations.
XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) has identified a significant market opportunity for its oral dissolvable (ODF) biosensor screening tests focused on oral inflammation, particularly linked to buprenorphine medications for opioid use disorder. The FDA has issued warnings on dental issues associated with these medications, indicating a market potential estimated to exceed USD $10.9 billion by 2027. XPhyto's initial ODF biosensor for general oral inflammation is EU-registered and aims to facilitate early detection of buprenorphine-related dental problems. The company's biosensor portfolio targets a potential combined market of US $42 billion by 2027.
XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) has identified a significant market opportunity for its oral dissolvable biosensor screening tests for oral inflammation, particularly concerning dental issues linked to buprenorphine medications used for opioid use disorder. The FDA has acknowledged serious dental problems associated with these drugs and continues to recommend their use. XPhyto's biosensor product is designed for simple, low-cost detection of inflammation and has already been registered for marketing in Europe. The global buprenorphine market is projected to exceed USD $10.9 billion by 2027.
XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF) has appointed Dr. Florian A. Sahr as Head of Project Management for its European operations. Dr. Sahr brings extensive experience in drug formulation and GMP-compliant manufacturing. His previous roles include Senior Scientist at Gen-Plus GmbH and Project Manager at tesa Labtec GmbH, focusing on transdermal and oral dissolvable drug delivery systems. Dr. Sahr will oversee product development at Vektor Pharma, XPhyto's German subsidiary, as the company explores manufacturing options for its oral dissolvable biosensors.
XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) has released a product development report on its Rotigotine transdermal patch, detailing positive results from a recent human cadaver skin permeation study. This study, part of the formula optimization process at its German subsidiary, Vektor Pharma, demonstrates absorption within the target range of existing formulations. The company is preparing for a pivotal study in Q4 2022, aiming for regulatory approval in the EU. The global transdermal patch market is projected to grow from $6.5 billion to $20 billion by 2028.
XPhyto Therapeutics Corp. has released a development report on its sublingual oral dissolvable film (ODF) biosensor pipeline, showcasing innovative technologies from its subsidiaries, Vektor Pharma and 3a-diagnostics. The integrated platform aims for rapid commercialization of biosensors targeting bacterial and viral infections, particularly in oral health. The biosensor market is projected to reach US$42 billion by 2027. The Company plans to prioritize commercialization in the oral health sector, with potential earnings from a global dental services market valued at US$435 billion in 2021. XPhyto is focused on regulatory approvals in Europe.
XPhyto Therapeutics Corp. has released a market and product development report on its Rotigotine transdermal patch, designed for Parkinson's disease and restless legs syndrome. This patch, developed via the TDS platform by its subsidiary Vektor, enhances drug bioavailability with a steady 24-hour supply. The global market for Rotigotine patches was valued at approximately US$518 million in 2021 and is projected to exceed US$766 million by 2030. Following a successful bioavailability study, XPhyto plans to advance to a pivotal study in Q4 2022.
XPhyto Therapeutics Corp. has successfully closed the first tranche of its private placement, issuing 1,250,000 common shares at $1.00 each, raising a total of $1,250,000. The Company incurred $100,000 in finder’s fees and issued 100,000 finder's warrants, each exercisable at $1.00 for two years. Proceeds will support the development of its drug formulations, diagnostic products, and working capital needs. XPhyto is focused on next-generation therapies and operates in North America and Europe, particularly Germany.
XPhyto Therapeutics provides an update on its subsidiary XPhyto Laboratories, focusing on psychedelic medicine programs in Canada and Germany. The company is advancing its research on mescaline, having synthesized approximately 60 g of GMP-grade mescaline with over 99% purity. XPhyto is developing a novel drug delivery system to improve dosing predictability and reduce side effects. In Germany, they are creating industrial-scale production methods for GMP psilocybin. A Phase I clinical trial for mescaline is planned to begin in late 2022.
FAQ
What is the market cap of XPHYF (XPHYF)?
